Orthocell Ltd · ASX:OCC
Orthocell — 28th Annual ROTH Conference (March 2016)
20 slides from Orthocell's conference presentation, Mar 15, 2016
Slide 1: 28th Annual ROTH Conference Investor Presentation
For personal use only 28th Annual ROTH Conference Investor Presentation March 2016 ASX: OCC Paul Anderson Managing Director
Slide 2: Disclaimer
Disclaimer For personal use only This presentation prepared by Orthocell Pty Ltd ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall ther
Slide 3: MSK Demographic Status
MSK Demographic Status For personal use only Orthopaedic Wave > Cost Effectiveness > Investment Radar MSK Regenerative Medicine Growth Factors Cellular Collagen Growth Therapies Scaffolds Factors 3
Slide 4: Company Overview
Company Overview For personal use only Orthocell Ltd is a regenerative medicine company developing cellular therapies, collagen scaffolds and growth factors for the treatment of human tendons, ligaments and soft tissue defects • Founded in 2006, headquartered in Australia, ASX listed August 2014 • U
Slide 5: Positioned for growth
Positioned for growth For personal use only OCC is deal ready and positioned for growth: Clinically validated and Next product in late Global approvals and marketed treatments stage development expansion underway Key areas of investment in MSK regenerative medicine by Pharma and Large Cap Biotechs:
Slide 6: Product overview
Product overview For personal use only Cell Therapies Product Development Stage Approval Status Current Applications World 1st Tendon Commercial Marketed in Australia Tennis elbow, achilles, Regeneration -Ortho-ATI™ Clinical in US/EU gluteal, patellar, rotator cuff Ortho-ACI™ Commercial Marketed in
Slide 7: Cellular Therapies
ortho cell ortho Cellular Collagen Pipeline Therapies Scaffolds For personal use only at
Slide 8: Ortho-ATI – Autologous Tenocyte Implantation
Ortho-ATI™ – Autologous Tenocyte Implantation For personal use only Ortho-ATI™ is a stem cell therapy to regenerate tendons and ligaments: • Autologous cell therapy to regenerate tendon tissue • enables healing of tendons, reduces pain and increases strength • greatly improves the patient’s mobility
Slide 9: Ortho-ATI 4.5 yr. clinical data
Ortho-ATI™ 4.5 yr. clinical data For personal use only Ortho-ATI™ tennis elbow study: • 20 patients that had failed all other treatments, with average 31 month symptoms on • Patients improved significantly with 1 patient proceeding to surgery • Data to 4.5 years recently published in American Journa
Slide 10: Positioning Ortho-ATI
Positioning Ortho-ATI™ For personal use only Market leading world first tendon regeneration treatment Over 300 patients treated to date. Demonstrated pathway to market Non operative procedure with high cost- benefit outcomes Directly addresses the underlying pathology of tendinopathy (disease modify
Slide 11: Ortho-ATI expansion plans
Ortho-ATI™ expansion plans For personal use only Bringing Ortho-ATI™ to the world’s largest markets: • IND being prepared for US Phase 2 tennis elbow study • partnering discussions ongoing with US and EU potential partners • discussions in Japan underway to leverage abridged approval process Austral
Slide 12: Ortho-ACI - Autologous Chondrocyte Implantation
Ortho-ACI™ - Autologous Chondrocyte Implantation For personal use only Ortho-ACI™ - Offers an effective treatment for symptomatic defects of the articulating cartilage of the joints, predominately the knee and ankle. Ortho-ACI™ - 2 stage procedure: Biopsy and chondrocyte cultivation followed by cell
Slide 13: Collagen Scaffolds
ortho cell A ortho cell Cellular | Collagen Pipeline Therapies 1 Scaffolds , For personal use only
Slide 14: Collagen Scaffold Platform – CelGro
Collagen Scaffold Platform – CelGro™ For personal use only CelGro™ is a superior soft tissue regeneration technology: Significantly differentiated: • Structure - mechanical • Use – bio-degradable • Origin - bio compatable Multiple applications with significant market potential: Clinical Trial Stage
Slide 15: CelGro path to market
CelGro™ path to market For personal use only Regulatory pathway • CE Mark submission being finalised for submission targeting an approval in 2016 • FDA 510(k) submission planned for late 2016 • Other international markets to follow Pursuing direct sales as well as licence opportunities: • dental, or
Slide 16: Pipeline
ernetel orthoen Cellular Collagen Therapies Scaffolds Pipeline
Slide 17: Next generation pipeline
Next generation pipeline For personal use only Strong product pipeline: Celgro • collagen powder for bone void fillers • guided nerve regeneration • braided ligament and ACL replacement Lab Grown Tendons • laboratory manufactured human tendon • replacement tendons for hands and other applications Gr
Slide 18: Corporate Overview
Corporate Overview For personal use only Corporate Team ASX OCC CEO Paul • Verigen Share Price AU$0.40 Anderson • Genzyme • Biomet Ordinary Shares 91.5 million on issue CSO Prof Ming • Verigen Hao Zheng • Genzyme Market Cap AU $37 million • UWA US $ 29 million Executive Dr Stewart • Cynata Options &
Slide 19: Recent Recognition / For further information contact
Recent Recognition For personal use only For further information contact www.Orthocell.com.au 19
Slide 20: Orthocell Ltd – Regenerating Mobility
For personal use only Orthocell Ltd Regenerating Mobility Paul Anderson Managing Director